Hofseth Biocare ASA (HOFBF) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The study “A Randomized Controlled Clinical Trial Assessing the Impact of 14-week Natural Salmon Oil Supplementation (CARDIO®)…” tests how Hofseth Biocare’s natural salmon oil changes the omega-3 index in healthy adults and affects heart and inflammation markers. It matters because a higher omega-3 index is linked to better heart health, but many standard omega-3 pills have not matched the benefits seen from eating fish.
The trial compares Hofseth’s minimally processed salmon oil soft gels, marketed as CARDIO, with a standard processed cod liver oil supplement. Both are dietary supplements, but CARDIO keeps the full spectrum of fatty acids found in salmon, aiming to show a stronger and broader health effect than traditional omega-3 concentrates.
The study is an interventional trial where participants are randomly assigned to one of the two supplements, so the groups should be comparable. It uses a parallel design with no blinding, and the main goal is prevention, meaning it looks at improving risk markers in generally healthy adults rather than treating disease.
The trial started after submission on 2025-01-27, and the overall status is now listed as completed, which means dosing and follow-up are done. The most recent update was filed on 2026-02-20, and no results have been posted yet, so investors know data has been collected but not formally disclosed on ClinicalTrials.gov.
For HOFBF, a completed head-to-head trial against standard cod liver oil is a potential catalyst, especially if CARDIO shows a larger omega-3 index rise or better cardiometabolic markers, which could support premium pricing and stronger positioning in the omega-3 category. Until results appear, the update mainly reduces execution risk but may not move the stock much, while peers in fish oil and nutraceuticals, such as large generic omega-3 makers, face headline risk if the data clearly favor whole-fish oils.
The study has been completed and recently updated, and further details will be available as results are posted on the ClinicalTrials portal.
To learn more about HOFBF’s potential, visit the Hofseth Biocare ASA drug pipeline page.